Yenepoya Research Centre, Yenepoya (Deemed to be University), Deralakatte, Mangalore - 575 018, Karnataka, India.
Curr Gene Ther. 2020;20(5):333-346. doi: 10.2174/1566523220666201012145731.
Respiratory diseases are one of the prime topics of concern in the current era due to improper diagnostics tools. Gene-editing therapy, like Clustered regularly interspaced palindromic repeats- associated nuclease 9 (CRISPR/Cas9), is gaining popularity in pulmonary research, opening up doors to invaluable insights on underlying mechanisms. CRISPR/Cas9 can be considered as a potential gene-editing tool with a scientific community that is helping in the advancement of knowledge in respiratory health and therapy. As an appealing therapeutic tool, we hereby explore the advanced research on the application of CRISPR/Cas9 tools in chronic respiratory diseases such as lung cancer, Acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF). We also address the urgent need to establish this gene-editing tool in various other lung diseases such as asthma, Chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF). The present review introduces CRISPR/Cas9 as a worthy application in targeting epithelial-mesenchymal transition and fibrinolytic system via editing specific genes. Thereby, based on the efficiency of CRISPR/Cas9, it can be considered as a promising therapeutic tool in respiratory health research.
呼吸系统疾病是当前时代人们关注的主要课题之一，这主要是因为缺乏适当的诊断工具。基因编辑疗法，如成簇规律间隔短回文重复相关核酸酶 9（CRISPR/Cas9），在肺部研究中越来越受欢迎，为深入了解潜在机制开辟了道路。CRISPR/Cas9 可以被视为一种有潜力的基因编辑工具，科学界正在利用它来推动呼吸健康和治疗方面的知识进步。作为一种有吸引力的治疗工具，我们在此探讨了 CRISPR/Cas9 工具在肺癌、急性呼吸窘迫综合征（ARDS）和囊性纤维化（CF）等慢性呼吸系统疾病中的应用的高级研究。我们还强调了迫切需要在哮喘、慢性阻塞性肺疾病（COPD）和特发性肺纤维化（IPF）等其他各种肺部疾病中建立这种基因编辑工具。本综述介绍了 CRISPR/Cas9 通过编辑特定基因在靶向上皮-间充质转化和纤维蛋白溶解系统方面的应用。因此，基于 CRISPR/Cas9 的效率，它可以被视为呼吸健康研究中一种很有前途的治疗工具。
